Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
- 주제(키워드) Head and neck neoplasms , Biomarkers , Immune check point , Platinum refractory , Sum of target lesions
- 주제(기타) Oncology
- 설명문(일반) [Lee, Yun-Gyoo] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Sch Med, Seoul, South Korea; [Chang, Hyun] Catholic Kwandong Univ, Dept Internal Med, Int St Marys Hosp, Coll Med, Incheon, South Korea; [Keam, Bhumsuk] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Chun, Sang Hoon] Catholic Univ Korea, Coll Med, Dept Internal Med, Bucheon St Marys Hosp, Bucheon, South Korea; [Park, Jihyun] Konkuk Univ, Sch Med, Dept Internal Med, Med Ctr, Seoul, South Korea; [Park, Keon Uk] Keimyung Univ, Dept Hematooncol, Dongsan Med Ctr, Daegu, South Korea; [Shin, Seong Hoon] Kosin Univ, Coll Med, Dept Internal Med, Gospel Hosp, Busan, South Korea; [An, Ho Jung] Catholic Univ Korea, Coll Med, Dept Internal Med, St Vincents Hosp, Seoul, South Korea; [Lee, Kyoung Eun] Ewha Womans Univ Hosp, Dept Hematol & Oncol, Seoul, South Korea; [Lee, Keun-Wook] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; [Kim, Hye Ryun] Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Coll Med, Seoul, South Korea; [Kim, Sung-Bae] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Coll Med, Seoul, South Korea; [Ahn, Myung-Ju] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea; [Hwang, In Gyu] Chung Ang Univ, Chung Ang Univ Hosp, Dept Internal Med, Coll Med, 102 Heukseok Ro, Seoul 06973, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 KOREAN CANCER ASSOCIATION
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000182287
- 본문언어 영어
- Published As http://dx.doi.org/10.4143/crt.2020.824
초록/요약
Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results The patients received anti & ndash;programmed cell death protein-1 (PD-1) (n=73, 58%), anti & ndash;programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti & ndash;PD-1/PD-L1 and anti & ndash;cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI.
more